Elanco finalizes acquisition of AHV International
Elanco Animal Health has completed its acquisition of AHV International, a Dutch innovator in farm animal health, expanding Elanco's presence in the global dairy market. This acquisition will allow Elanco to offer an expanded portfolio of products to improve transition cow health, well-being, and productivity, enhancing dairy producers' ability to meet the rising global demand for milk. The deal aims to integrate AHV’s innovative tools, such as StopLac and Quorum Sensing Technology, to support animal welfare, sustainability, and reduce the need for antibiotics in dairy farming.
MAY 14·Indianapolis Business Journal▼
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products
Elanco has agreed to a $9.3 million settlement with consumers to resolve antitrust allegations related to its flea and tick prevention products. While Elanco disputes the allegations, the settlement aims to resolve claims that the company used anti-competitive tactics. This development follows a period of scrutiny over the pharmaceutical industry's practices.
MAR 19·Stock Titan▲
Former Elanco director joins ImmuCell board in calf-health push
ImmuCell (Nasdaq: ICCC) has appointed Kathy Turner, a former director at Elanco Animal Health with over 30 years of global commercial leadership experience, to its Board of Directors, effective April 1, 2026. She will replace Steven Rosgen and chair the Compensation and Stock Option Committee while also serving on the Audit Committee. Turner's extensive background is expected to bolster ImmuCell's efforts to expand the reach of its First Defense® product line internationally.
